Brian Weisner BS*, Diana Shechtman OD**, Aaron Gold OD***, Timothy Murray MD***
A 41-year-old Caucasian male optometry student presented to the clinic for evaluation of previously diagnosed choroidal nevus OD. The patient had no complaints of any vision loss or visual disturbances. Past ocular history revealed a PED OD overlying with a choroidal nevus, (1.5DD) adjacent the optic nerve (Fig 1 shows previous OCT of nevus with associated PEDs). This was monitored on an annual basis since initially discovered in 2018. BCVA’s today was 20/20 OD and OS. Dilated fundus examination today confirmed previous findings of choroidal lesion adjacent to the optic nerve (see color fundus photo “CPF” Fig 2a and FAF hyporeflective lesion adjacent to the ONH Fig 2b). On note, FAF showed no associated lipofuscin. SDOCT today revealed PED with associated new subretinal fluid (SRF) overlying the choroidal lesion (Fig 3). Ultrasound did not show any significant thickness or abnormalities. Although the lesion remained stable with regards to size, given the new SRF finding, he was a diagnosed with an atypical nevus with overlying serous PED. Given the new finding of SRF, the patient is currently being followed by retinal ocular oncology every 3 months to monitored for any changes in size/appearance and to initiate further intervention when necessary. The patient was also asked to start Dorzolamide BID in OD.
Choroidal Nevus vs Choroidal Melanoma
Choroidal nevi are benign melanocytic lesions of the posterior uvea. These choroidal lesions are often described as stable pigmented small flat lesions. Overlying drusen, depigmented halos, RPE changes and even CNV may be associated with such lesions. Six percent of the population manifest a choroidal nevus. About 1 in 8800 of such choroidal nevi may transform to a choroidal melanoma. Given the fact that choroidal melanoma is associated with increase ocular morbidity as well as, increase mortality, it is imperative to differentiating between benign choroidal nevi and small malignant choroidal melanoma or those that have the propensity to transform. Yet, this may at times pose some challenges. Numerous studies have expanded on the assessment of specific characteristics observed in a choroidal lesion, which may in fact increase the propensity toward a choroidal melanoma. Mnemonics and acronyms, such as TFSOM (UHD), TFSOM-DIM and MOLES, have all been used to address such ominous characteristics. Ominous findings include but are not limited to:
Thickness > 2 mm
Subretinal Fluid present
Symptoms (i.e. decreased vision, flashes or floaters, visual field defect)
Orange pigment (lipofuscin)
Margin of the lesion withing 3 mm of optic disc
Ultrasonographic hollowness, mushroom shape, low-medium internal reflectivity of a thickened lesion
Absence of surrounding halo
Absence of Drusen
Diameter > 5mm
Diagnostic Modalities
Diagnostic modalities used in the assessment of a choroidal lesion may help discern a benign choroidal nevus from atypical or suspicious lesion. Ultrasound is the primary diagnostic test use in the evaluation of choroidal lesion. Characteristic shape as well as diameter size, thickness, and acoustic characteristics may be denoted in an ultrasound. A readily accessible and common diagnostic tool use in the evaluation of a choroidal lesion is serial color fundus photography (CPF). CPF is especially helpful in documenting progression. Additionally, FAF aids in the evaluation of associated findings such as lipofuscin. SD-OCT has also been commonly employed, helping to assess associated findings such as fluid, shaggy PIL, drusen and may further help in the evaluation of the lesion. Although other tests such as FA & ICGA have been used in the evaluation of choroidal lesion, these are not commonly employed.
Management
Given the atypical signs of new sub retinal fluid, the patient is being monitored closely by the retinal oncologist. As ODs, it is imperative to identify a high-risk choroidal lesion or atypical/suspicious nevus. Especially since early diagnosis is crucial to decrease further complications. These patients should be watched frequently and often co-managed with retinal specialists / retinal oncologists to assure proper and prompt management and treatment.
Of note, the use of dorzolamide has shown to have a positive impact on management of macular edema and macular-schisis. Given the fact that there are possible beneficial effects in reducing the size of the serous spaces, it was implemented in this case.
* actual patient
** Loh Ophthalmology & Retina Consults of Miami
*** Murray Ocular Oncology & Retina
References
- https://www.aao.org/eyenet/article/distinguishing-choroidal-nevus-from-choroidal-mela
- Mashayekhi A, Siu S, Shields CL, et al. Slow enlargement of choroidal nevi: a long-term follow-up study. Ophthalmology. 2011;118(2):382-388.
- Shields CL et al. Arch Ophthalmol. 2000;118(3):360-364.
- Shields CL, Dalvin LA, Ancona-Lezama D, et al. Choroidal nevus imaging features in 3,806 cases and risk factors for transformation into melanoma in 2,355 cases: The 2020 Taylor R. Smith and Victor T. Curtin Lecture. Retina. 2019;39(10):1840-1851.
- Roelofs KA, O’Day R, Harby LA, et al. The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe? Cancers (Basel). 2020;12(5):1311.
- Shields CL, Lim LS, Dalvin LA, et al. Small choroidal melanoma detection with multimodal imaging and management with plaque radiotherapy or AU-011 nanoparticle therapy. Curr Opin Ophthalmol. March 5, 2019
- Sumich P, Mitchell P, Wang JJ. Choroidal nevi in a white population: The Blue Mountains Eye Study. Arch Ophthalmol.1998;116(5):645-650.
- Shahsuvaryan ML. Carbonic anhydrase inhibitors in the management of macular edema: A review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2022 Apr 1;11(1):34-41.




